Enterprise Financial Services Corp Argenx Se Transaction History

Enterprise Financial Services Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$295.0 - $350.58 $2,950 - $3,505	-10 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$257.11 - $319.92 $2,056 - $2,559	-8 Reduced 44.44%	10 $3,000
Q1 2021 May 13, 2021	BUY	$268.3 - $380.31 $2,146 - $3,042	8 Added 80.0%	18 $5,000
Q4 2020 Feb 12, 2021	SELL	$248.13 - $308.36 $992 - $1,233	-4 Reduced 28.57%	10 $3,000
Q3 2020 Nov 13, 2020	BUY	$215.51 - $272.51 $3,017 - $3,815	14 New	14 $4,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.5B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Enterprise Financial Services Corp, based on Form 13F filings with the SEC.

Stay updated on Enterprise Financial Services Corp with notifications on news.